Velkommen til Campus Sanofi for sundhedspersoner
Har du allerede en konto til Campus Sanofi? Tilmeld dig for at modtage personlige beskeder
Artikel
What is PRALUENT®(alirocumab)?
PRALUENT: a PCSK9i that ticks all the boxes1–4 PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.2 It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.2 Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.1
Why choose PRALUENT®?
The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2
Gaucher disease in children
Gaucher disease is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GBA1 gene, resulting in deficient activity of the enzyme acid β glucosidase.
DUPIREAL: Two-Year Turning Point with Dupilumab in CRSwNP
The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.2,3
Uddannelse
The Evolving Landscape of Disease Modification in Atopic Dermatitis - Current Evidence and Future Directions
Ekspertvideo: Kompleks type 2-inflammation – forklaret på en overskuelig måde
Professor Lipworth giver i denne video en kortfattet faglig gennemgang ved hjælp af den såkaldte bucket model.
Podcasts
Polyp Gossip
Polyp Gossip is a video podcast dedicated to exploring Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Hosted by two globally recognized rhinologists. The show delves into trending topics, latest advancements, and patient experiences.
The Hematology Podcast
Welcome to The Hematology Podcast, your source for the latest insights into hematology and rare blood disorders. This podcast covers cutting-edge research, clinical advancements, and real-world cases tailored for healthcare professionals.
A heart for Fabry - Podcast
A podcast series designed by cardiologists, for cardiologists and other healthcare professionals.
Hot topics in atopic dermatitis
This podcast episode highlights an engaging discussion on managing atopic dermatitis, featuring Dr. Andrew Pink, a consultant dermatologist from UK. Emmanuel Tony and Ashlyn Kerry guide the conversation. Dr. Pink discusses the challenges and strategies in treating eczema, emphasizing personalized treatment plans and the importance of patient communication.
RespTalks
Resptalks er en række af videnskabelige webinars og podcasts inden for emner som relaterer til det respiratoriske sygdomme som som astma, kronisk rhinosinuitis med næsepolypper til type 2 inflammation og meget andet. Indholdet er målrettet lungelæger, øre-næse-halslæger, allergologer, børnelæger, forskere fra de nordiske- og BeNeLux landene.
Treatable Traits & Asthma
En podcast om "treatable traits" ved astma med professor Backer, Pavord og Gibson. Denne podcast er for sundhedspersonale, der er interesseret i at lære mere om, hvordan man behandler astmapatienter på den mest optimale måde i henhold til tilgængelig videnskab og kliniske erfaringer.
Podcast om Min Sjældne Sygdom
I podcastserien ”Min Sjældne Sygdom” inviterer vært Bo Rafn, Medicinsk Rådgiver fra Sanofi, en af Danmarks førende specialister i studiet for at tale om et sjældent sygdomsområde. Sammen med eksperten i hver episode giver de lytteren en unik mulighed for at få indblik i symptomer, diagnose og hvordan man som patient, skal leve med en sjælden sygdom.